Characteristics of Pharmacists' Interventions Related to Proton-Pump Inhibitors in French Hospitals: An Observational Study

Methods The study was based on a retrospective analysis of pharmacist interventions for DRPs detected during the medication order review and documented into the French Act-IP© database over a 12-year period. DRPs and PIs were analyzed, and independent factors of physician acceptance were assessed via multiple logistic regression. Results Out of the 620,620 PIs registered, 29,694 targeted a PPI (4.8%). PPI's DRPs were mostly related to the prescription of a “drug not available at the hospital” (26.1%) and a “drug use without indication” (18.3%); PIs were mostly “drug switch” (35.9%) and “drug discontinuation” (26.1%). In all, 18,919 PIs were accepted by physicians (63.7%). Acceptance was significantly associated with patient age: less accepted for the 18–75 years group (OR = 0.59, 95 CI [0.46–0.76]), and the >75 years group (OR = 0.57, 95 CI [0.44–0.73]) vs. <18 years group; for the type of DRP, “drug use without indication” was the less accepted (OR = 0.73, 95 CI [0.63–0.85]); for the type of PI, “dose adjustment” was the less accepted (OR = 0.32, 95 CI [0.23–0.45]). Conclusion Pharmacists contribute to preventing DRPs associated with PPI prescriptions during the medication order review process. Moreover, they often detect PPIs used without indication and they propose drug discontinuation, which contributes to the PPI deprescribing process. PIs should be further developed in the future to reduce PPI overprescription.

[1]  P. Kahrilas,et al.  Umbrella review of 42 systematic reviews with meta‐analyses: the safety of proton pump inhibitors , 2021, Alimentary pharmacology & therapeutics.

[2]  S. Valette,et al.  [Evaluation of the implantation of a de-prescribing process for proton pump inhibitor (PPI) using an algorithm within an internal medicine department]. , 2020, La Revue de medecine interne.

[3]  P. Katz,et al.  Reported proton pump inhibitor side effects: what are physician and patient perspectives and behaviour patterns? , 2020, Alimentary pharmacology & therapeutics.

[4]  A. Singer,et al.  Improving care for elderly patients living with polypharmacy: protocol for a pragmatic cluster randomized trial in community-based primary care practices in Canada , 2019, Implementation Science.

[5]  A. Dinh,et al.  Proton pump inhibitors: why this gap between guidelines and prescribing practices in geriatrics? , 2019, European Journal of Clinical Pharmacology.

[6]  P. Tugwell,et al.  Continuation or deprescribing of proton pump inhibitors: A consult patient decision aid , 2018, Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC.

[7]  C. Tannenbaum,et al.  Deprescribing conversations: a closer look at prescriber–patient communication , 2018, Therapeutic advances in drug safety.

[8]  Raja Tamaz,et al.  Inappropriate Prescription of Proton Pump Inhibitors in a Community Setting. , 2018, The Canadian journal of hospital pharmacy.

[9]  P. Moayyedi,et al.  Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline. , 2017, Canadian family physician Medecin de famille canadien.

[10]  E. Savarino,et al.  The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal. , 2017, European journal of internal medicine.

[11]  A. Zullo,et al.  Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression , 2016, BMC Medicine.

[12]  Djb Marks,et al.  Time to halt the overprescribing of proton pump inhibitors , 2016 .

[13]  K. Thavorn,et al.  Effect of a Proton Pump Inhibitor Deprescribing Guideline on Drug Usage and Costs in Long-Term Care. , 2016, Journal of the American Medical Directors Association.

[14]  A. Rauss,et al.  The clinical impact of medication reconciliation on admission to a French hospital: a prospective observational study , 2015, European journal of hospital pharmacy. Science and practice.

[15]  S. Janković,et al.  Pharmaceutical care in a long-stay psychiatric hospital , 2015, European journal of hospital pharmacy. Science and practice.

[16]  C. Mouchoux,et al.  [Pharmacist's interventions on proton pump inhibitor prescriptions in a University Hospital]. , 2015, Journal de pharmacie de Belgique.

[17]  E. McDonald,et al.  Reduction of inappropriate exit prescriptions for proton pump inhibitors: A before-after study using education paired with a web-based quality-improvement tool. , 2015, Journal of hospital medicine.

[18]  B. Allenet,et al.  Trends in pharmacists' medication order review in French hospitals from 2006 to 2009: analysis of pharmacists' interventions from the Act‐IP© website observatory , 2015, Journal of clinical pharmacy and therapeutics.

[19]  B. Charpiat,et al.  Effets indésirables émergents des inhibiteurs de la pompe à protons , 2013 .

[20]  C. Mouchoux,et al.  [Emergent adverse effects of proton pump inhibitors]. , 2013, Presse medicale.

[21]  A. Goodman,et al.  Physicians’ Opinions of Stress Ulcer Prophylaxis: Survey Results from a Large Urban Medical Center , 2013, Digestive Diseases and Sciences.

[22]  A. Mangoni,et al.  Inappropriate Prescribing of Proton Pump Inhibitors in Older Patients , 2012, Drugs & Aging.

[23]  D. Metz,et al.  Proton pump inhibitors: are they overutilised in clinical practice and do they pose significant risk? , 2012, International journal of clinical practice.

[24]  J. Heidelbaugh,et al.  Overutilization of proton-pump inhibitors: what the clinician needs to know , 2012, Therapeutic advances in gastroenterology.

[25]  M. Alsultan,et al.  Pattern of Intravenous Proton Pump Inhibitors Use in ICU and Non-ICU Setting: A Prospective Observational Study , 2010, Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association.

[26]  E. Culley,et al.  Longitudinal Analysis of the Costs Associated with Inpatient Initiation and Subsequent Outpatient Continuation of Proton Pump Inhibitor Therapy for Stress Ulcer Prophylaxis in a Large Managed Care Organization , 2010, Journal of managed care pharmacy : JMCP.

[27]  P. Durieux,et al.  Long-term effects of a multifaceted intervention to encourage the choice of the oral route for proton pump inhibitors: an interrupted time-series analysis , 2009, Quality & Safety in Health Care.

[28]  J. Inadomi,et al.  Overutilization of Proton Pump Inhibitors: A Review of Cost-Effectiveness and Risk in PPI , 2009, The American Journal of Gastroenterology.

[29]  B. Allenet,et al.  Assessment of Clinical Pharmacists' Interventions in French Hospitals: Results of a Multicenter Study , 2008, The Annals of pharmacotherapy.

[30]  I. Forgacs,et al.  Overprescribing proton pump inhibitors , 2008, BMJ : British Medical Journal.

[31]  M. Juste,et al.  Site internet de la Société française de pharmacie clinique pour l’analyse des interventions pharmaceutiques : finalité, mode d’emploi et perspectives , 2007 .

[32]  B. Allenet,et al.  Validation of an instrument for the documentation of clinical pharmacists’ interventions , 2006, Pharmacy World and Science.

[33]  Michael J Dooley,et al.  A prospective multicentre study of pharmacist initiated changes to drug therapy and patient management in acute care government funded hospitals. , 2004, British journal of clinical pharmacology.

[34]  A. Blenkinsopp,et al.  The rise and rise of proton pump inhibitor drugs: patients' perspectives. , 1997, Social science & medicine.